Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SCHEARLY: Subcutaneous Trastuzumab in HER2+ Breast Cancer
NCT01940497Phase 3Completed
- Sponsor
- Roche
- Start
- Nov 2013
- Primary completion
- Apr 2016
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of trastuzumab in breast cancer, sponsored by Roche. Started Nov 2013; status: completed.
02
Drugs
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT01940497.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01940497.